Latest News

16th November 2017

Centauri Therapeutcs

New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance

  • 2017 marks the beginning of a strong collective fight aimed at setting up initiatives to combat antimicrobial resistance (AMR) on a national and international level
  • European BEAM Alliance emphasises key role of small and medium-sized enterprises (SMEs) as major innovators and presents a set of guidelines on how to more effectively reinforce and support antibacterial research and development (R&D) by SMEs
  • Globally, some 250 biotech companies are focusing on developing new drugs to combat AMR - The 40 BEAM members alone have more than 100 new drug candidates in their pipelines including many novel breakthrough approaches

Paris (France), November 16th, 2017 - In 2017, the collective fight to combat antimicrobial resistance (AMR) has experienced 

a new upswing. Following the eye-opening report of British economist Lord Jim O’Neill, policymakers, funding bodies and national governments set up a series of new initiatives to accelerate drug development by supporting research and development (R&D) in the AMR field.

Taking advantage of the World Antibiotic Awareness Week (WHO) and 2 days before the European Antibiotic Awareness Day (Nov 18, 2017), the European BEAM alliance, representing 40 ‘Biopharmaceutical companies from Europe innovating in AntiMicrobial resistance’ research, today released a position paper to acknowledge these efforts and to highlight the important role that small and medium-sized enterprises (SMEs) are playing as innovators.

The document lists ten (10) guidelines as to how antibacterial R&D could be revived and proposes specific support for SME-driven innovation in the AMR field. The alliance particularly demands that policymakers understand the specific nature and needs of SMEs to design effective PUSH and PULL mechanisms.

1. Adequately-shaped incentive mechanisms that ultimately rewards R&D evidence

2. Health Technology Assessment recognising the true value of SME innovation

3. Dedicated regulatory pathways to support the specific needs of AMR projects and act as pre-qualification criteria to some PUSH/PULL incentive mechanisms

4. PUSH incentives and funding mechanisms that are directed to SMEs, calibrated and accessible for SMEs in practice

5. Calibrated Market Entry Rewards (MER) to ensure continuous and sustainable innovation from academics to biotech companies and to large pharma players

6. R&D prizes and phase entry rewards as effective PULL mechanisms for SMEs to incentivise the most underserved indications in AMR

7. Targeted tax incentives specifically addressing SMEs to incentivise private investments into AMR-focused companies and/or avoid de-prioritization

8. Going beyond to exploit all possibilities for AMR from SMEs

9. Support education to strengthen attractiveness of the field for R&D professionals/scientists

10. Long term thinking and wisely usage of AMR innovations combined with appropriate diagnostics development

www.beam-alliance.eu

 

Marie Petit, coordinator of the BEAM alliance, says: “Existing SMEs in the AMR field are true pioneers! Despite a much-underserved ecosystem to fund and perform R&D, they fight to make the difference for millions of patients and come up with very innovative approaches – both antibacterial and non-antibacterial (prevention, anti-virulence, anti-biofilm, phages, microbiome protection...). They carry the hope for the coming decades and it is of upmost importance that policymakers and countries involved in the fight against AMR make sure their policies are laser focused on SMEs need and none is left behind until the ecosystem is properly revived.

 

Due to their versatile properties, bacteria are evolving resistance faster than policymakers are implementing action. It is of enormous importance to ultimately revive R&D in AMR by developing compelling surveillance data, encouraging out-of-the-box thinking, rewarding R&D evidence and strengthening existing scientific expertise.” adds Marc Gitzinger, CEO of BioVersys AG, Switzerland, Vice-President of the BEAM Alliance.

 

Marc Lemonnier, CEO of Antabio SAS, France, Member of the Management Board of the BEAM Alliance comments: “Globally, some 250 SMEs are working on new antibacterial strategies. SMEs are the crucial innovation engine in the AMR field. Addressing the specific requirements of SME-driven innovation within current AMR initiatives is key in order to provide patients with effective drugs that can win the fight against AMR.

 

Mike Westby, CEO of Centauri Therapeutics: “The BEAM Alliance Position Paper, released today during World Antibiotic Awareness Week (WHO), highlights the important role of SMEs in discovering new ways to treat life-threatening infections caused by multi-drug resistant pathogens (‘Superbugs’). The Paper calls on policy makers to act now and implement a range of PUSH and PULL incentives to truly invigorate investment in SME-driven innovation. Centauri is proud to be a member of the BEAM Alliance and we are confident that positive change will continue to be achieved through such coordinated efforts.

 

In March 2018, the BEAM alliance together with Berlin-based BIOCOM AG will invite key players to a one-day-conference, providing a discussion platform for addressing the specific challenges of SMEs in developing new antimicrobials and AMR diagnostics. The Berlin Conference 2018 expects more than 200 high-level representatives from policy, academia, industry and the finance sector. “We will have more than 40 speakers, among them over half from SMEs, to explore the best business strategies in the AMR R&D arena.” says Sandra Wirsching from BIOCOM AG, a life science-focused publishing house. The event is further supported by the German Fraunhofer Society and the EU-funded "European Gram Negative Anti-Bacterial Engine" (ENABLE) consortium.

To have full access to the BEAM Alliance position paper 2017, please go to: www.beam-alliance.eu

About the BEAM Alliance:

The BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) plays a key role working on a European and national level to represent the interests of its 40 members. The BEAM members are collectively developing more than 100 new compounds focused upon the cure and prevention of bacterial infections. They cover the whole range of pharmaceutical drug development from small molecule antibiotics, antibiotic combinations, phages, antibodies, prophylactic and therapeutic vaccines, peptides, prebiotics, other bioproducts, adjunctive therapies and medical devices, thus representing the large majority of all European companies actively working on AMR. The goal of the BEAM alliance is to maintain and promote awareness of SME-driven innovation in the field and to support policymakers in understanding economic business models around AMR. The BEAM alliance closely cooperates with all stakeholders dedicated to the fight against AMR.

About the Berlin Conference “Novel Antimicrobials & AMR diagnostics”

The “Berlin Conference on Life Sciences” was started eleven years ago as a BIOCOM event to discuss promising developments in the biotech and pharma business in Europe. For the second year in a row, the Berlin Conference addresses the AMR market and its challenges. The one-day-event aims at building a broad discussion platform for relevant stakeholders in the field to help accelerating innovation. That there is a need of combined efforts is underlined by the rise of a multitude of global, European and national initiatives to support the development of new antimicrobials and diagnostics. The conference brings together people from science and business, investors and policy makers, start-ups and health economists, the public and private sector, to highlight the most promising technologies, to showcase best-practice examples and to discuss how to follow successful business strategies in the AMR market.

www.berlin-conferences.com

BEAM Alliance Member Companies: Abac Therapeutics – AiCuris Anti-infective Cures - Alaxia - Allecra Therapeutics - Antabio - AntibioTx - Arsanis - Auspherix - Basilea Pharmaceutica International - BioFilm Pharma - BioVersys - Centauri Therapeutics - Combioxin - Da Volterra - Debiopharm International - Deinobiotics/Deinove - Destiny Pharma - Discuva - Eligo Bioscience - Helperby Therapeutics - Karveel Pharmaceuticals - MaaT Pharma - Madam Therapeutics - Motif Bio - Mutabilis - Nabriva Therapeutics - Neem Biotech - Northern Antibiotics - Nosopharm - NovaBiotics - Pherecydes Pharma - Phico Therapeutics - Polyphor - QureTech Bio - Redx Anti-Infectives - Septeos - SetLance srl - Ultupharma - VaxDyn - Vibiosphen

BEAM Alliance Associated Member Companies: Bioaster - Vivexia

Ends


10th November 2017

Centauri Therapeutics CEO to present at US Superbugs Conference

Centauri Therapeutcs

 Screen Shot 2017 11 10 at 12.25.13

10th November - Dr Mike Westby, CEO of Centauri Therapeutics, will be presenting at the 2nd Annual Superbugs and Superdrugs conference in New York. The conference will be looking at new antibiotic developments and preventing antibiotic resistance.

Dr Westby will be discussing the use of immuno therapies as an alternative to antibiotics to treat Gram-negative infections.

Ends


3rd November 2017

Centauri Therapeutics presents at BioInfect 2017 

 

Centauri Therapeutcs

Manchester, 2nd November - Dr Emma Leire, lead microbiologist at Centauri Therapeutics, presented at BioInfect 2017 at Alderley Park. Emma discussed the use of Centauri’s technology platform to develop a drug that targets life threatening gram negative bacterial infections.

Ends


2nd November 2017

Centauri Head of Chemistry named in BioBusiness Awards

 

Centauri Therapeutcs

 

 

 

 

2nd November 2017 - Centauri’s Head of Synthetic Chemistry Mel Glossop, has been named as one of the top 50 Movers and Shakers in BioBusiness 2017 Celebrating leaders in UK healthcare business

The annual report identifies 50 women who have been recognised as leaders making an impact in a wide range of healthcare industry and research areas.

Mel is recognised for her work using programmable immunity to develop highly disruptive approaches to discovering drugs for the treatment of antimicrobial resistance and cancer. These bi-functional molecules combine several chemical disciplines, enabled through multiple global chemistry partnerships, and Mel has created a diverse patent portfolio leading to both private and public investment.

Mike Westby, CEO of Centauri Therapeutics Limited said: “I am very pleased to see that Mel has been recognised for the progress and contribution she is making to the success of Centauri. The list of 50 Movers and Shakers acknowledges excellence across our industry and it is great to see Mel’s name included.”

 

Ends


1st October 2017

Centauri welcomes Raul Elgueta

Centauri announced the appointment of Dr Raul Elgueta as Lead Immunologist. Dr. Elgueta will be responsible for the immunological characterisation of Centauri’s molecules across the portfolio and for the translational studies to predict efficacy in the patients.

Dr. Elgueta brings an extensive experience of development and research in immunology. Most recently, he served as an Operational Leader at Kings College London, where he led work focussing on stem cell in regenerative medicine program. Previously, he researched the role of B cells, T cells and dendritic cells in the context of transplantation and inflammatory disorders.

Dr Elgueta gained his Bachelor of Biological Sciences (BSc) at the Pontifical Catholic University of Chile and his PhD in Molecular and Cellular Biology at the University of Chile.

 

Centauri Therapeutcs

ENDS


11th September 2017

Centauri Therapeutics receives Innovate UK Biomedical Catalyst Award

Centauri Therapeutcs

  • Funding will be used to develop the Company’s Alphamer technology to target antibacterial resistance
  • The UK’s innovation agency will contribute up to £945K towards the project

London and Kent, UK, 11 September 2017:  Centauri Therapeutics Ltd (Centauri), a biotechnology company focused on the treatment of infectious diseases and cancer, announced today that it has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst (BMC) programme. Alongside backing from the Company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias, using the Company’s Alphamer™ technology.

Bacteria are continually evolving to resist new antibiotics, meaning new medicines are required to target novel drug-resistant strains and deliver effective therapies to patients. Centauri plans to develop an innovative treatment for patients suffering from infections caused by these resistant bacteria. Using the Company’s Alphamer drug mechanism, chemically synthesised molecules will redirect pre-existing antibodies to pathogens in a specific manner that elicits an immune response. This immune response will mediate destruction of the bacteria to clear the infection, while working in conjunction with existing antibiotics to reduce the dose and duration of therapy. Unlike traditional vaccines, this approach aims to treat infected patients and has the potential to elicit a broader immune response than monoclonal antibodies alone.

Dr Mike Westby, Director and CEO of Centauri Therapeutics, commenting on the award said: “The lack of new antibiotics combined with increasing incidence of bacterial resistance in the clinic has been termed ‘the perfect storm’ and there is an urgent need for innovative methods and efficacious therapies. The BMC Award is a significant recognition of Centauri’s scientific expertise and demonstrates the UK government’s confidence in our team’s ability to combat antibacterial resistance and deliver novel treatments for patients.”

Total costs for the project titled ‘Optimisation of antibody recruiting molecules as immunotherapeutics’ are estimated at £1.35M. The co-funding from Innovate UK will cover up to 70% of this, with Centauri’s investors supporting the remaining 30% of the project costs over a two-year period.

ENDS

 

Media enquiries

Lorna Cuddon, Zyme Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

+44 (0)7811 996 942

 

About Centauri Therapeutics Ltd www.centauritherapeutics.com

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.  Centauri is pursuing anti-bacterial opportunities on its own and immune-oncology opportunities through its joint venture with Horizon Discovery plc, Avvinity Therapeutics (Avvinity.com).

Centauri Therapeutics’ Executive team is led by Mike Westby, Chief Executive Officer (previously Pfizer, Roche) and Stuart Lawson, Chief Financial Officer (CEO of the private investment group Animatrix Capital LLP, and previously KPMG). Clive Dix is Non-Executive Director and Chairman of the Board (CEO of C4X Discovery and previously Convergence Pharmaceuticals, PowderMed, PowderJect, Glaxo Wellcome). Jonathan Synett is Managing Director of NCL Ventures, a specialist investment management firm focussing on high growth technology companies.

The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).

Centauri Therapeutics is based at Discovery Park, Kent.

 

About Alphamer™ Technology

The Alphamer™ technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection.

 

About Innovate UK and the Biomedical Catalyst 

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk

The Biomedical Catalyst (BMC) is a unique partnership between the MRC and Innovate UK, providing responsive and effective support to the most innovative life sciences opportunities regardless of scientific approach. The BMC aims to de-risk innovative science and commercialise ideas arising out of academia and industry helping UK SMEs to develop into competitive and sustainable organisations.  This accelerates the progress of novel products to market, facilitates onward investment and bridges “the valley of death”.

 


23rd August 2017

Centauri Therapeutics Ltd to attend The World Anti-Microbial Resistance Congress 2017

Centauri's CEO Mike Westby will be attending the World Anti-Microbial Resistance Congress in Washington from 14 - 15 September 2017. Please click on the banner below for more information.

 

World Anti-Microbial Resistance Congress

 


25th May 2017

Centauri Therapeutics Ltd revealed in the Future List of companies changing the way people live and work in Kent

Centauri has been revealed in the Future List as one of the twenty five companies changing the way people in Kent live and work. Selected by a team of expert judges, Centauri has been chosen as one of the group of firms that are developing and selling innovative products and services that are transforming lives for the better. Please click on the banner below for more information.

 


10th April 2017

Centauri Therapeutics Ltd to attend ECCMID and present at the event's Pipeline Corner 

Centauri's CEO Mike Westby and Microbiologist Emma Leire will be attending the 27th European Congress of Clinical Microbiology and Infectious Diseases in Vienna from 22 - 25 April 2017, where they have been invited to present an overview of the company's R & D pipelines and recent advances,  in the event's Pipeline Corner.  Please click on the banner below for more information 

ECCMID 

 


20th February 2017

Centauri Therapeutics Ltd closes £2.5m fundraising

Centauri Therapeutcs

  • Second tranche of seed financing secured, sufficient to develop first lead candidate through to proof of principle
  • £1.2m raised in oversubscribed completion of funding round

London and Kent, UK, 20th February 2017: Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, announced today that it has secured an additional £1.2m in funding to complete the seed round, the first tranche of which was raised in January 2016. The participants in the second tranche included existing investors and several new private investors. The funds raised will be used to take the Company’s first Alphamer drug candidate for anti-infective therapies through to preclinical proof of concept, a significant value inflection point in the program development, whilst progressing two other anti-bacterial candidates in parallel.  

Separately, Centauri is also actively progressing immune-oncology targets through Avvinity Therapeutics, its joint venture with Horizon Discovery Group plc, in which Horizon will invest up to £5.3 million over two tranches with the first tranche of £2.5m already committed.  Centauri’s focus on anti-microbial resistance and immuno-oncology medicines are priority markets for the worldwide healthcare agenda, which are forecast to reach a combined total of £100bn by 2020.

The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected targets. The molecules have two distinct parts: one end binds a cell-surface marker on the target (bacterial or tumour cell) using an aptamer, whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to the target in a specific manner and trigger an immediate immune response, so removing the target. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Mike Westby, CEO of Centauri Therapeutics, commented: “Progress at Centauri on both our anti-infectives and immuno-oncology programmes has been very positive, with the development and optimisation of candidate Alphamers running well ahead of schedule.  I am delighted with the continued support from our existing investors and I welcome our new investors to Centauri.”

ENDS

For more information please contact:

Lorna Cuddon, Zyme Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

+44 (0)7811 996 942

About Centauri Therapeutics Ltd (www.centauritherapeutics.com)

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.  Centauri is pursuing anti-bacterial opportunities on its own and immune-oncology opportunities through its joint venture with Horizon Discovery plc, Avvinity Therapeutics (Avvinity.com).

Centauri Therapeutics’ Executive team is led by Mike Westby, Chief Executive Officer (previously Pfizer, Roche) and Stuart Lawson, Chief Financial Officer (CEO of the private investment group Animatrix Capital LLP, and previously KPMG). Clive Dix is Non-Executive Director and Chairman of the Board (CEO of C4X Discovery and previously Convergence Pharmaceuticals, PowderMed, PowderJect, Glaxo Wellcome).

The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).

Centauri Therapeutics is based at Discovery Park, Kent.

 


1st February 2017

Centauri Board welcomes Jonathan Synett

Centauri Therapeutics Ltd is delighted to announce that Jonathan Synett has joined the Board of Directors.  Jonathan has extensive experience working with and investing in early stage, high growth businesses. Centauri extends warm thanks to Jerry Biggs who has recently stepped down as Director to pursue other ventures.

 
 

14th November 2016

Genesis 2016 Conference

Centauri Therapeutics Ltd will be attending the Genesis 2016 conference, where the overall theme will be "The Science, Technology and Business of 21st Century Biomedical Innovation".  The conference agenda will showcase success in the application of biomedical research, innovative technologies and leading edge business strategies in order to deliver effective benefits to patients globally.  For more information on the event, please click on the banner below. 

 

Genesis 2016

 


14th October 2016

Dr Mike Westby to speak at the Buck Institute for Research's Fall Conference. 

Buck Institue

 

The Buck Institute For Research on Aging will be holding their Fall Conference in Split Croatia, this weekend, 15th and 16th October. The conference theme is "Aging: Is Time Relative? An Adriatic Perspective" and Dr Mike Westby has been invited to speak at the event.  He will be delivering his speech entitled "Redirecting Host Immunity As A Therapeutic Approach For Diseases Caused By Anti-Microbial Resistant (AMR) Pathogens: Lessons From Cancer" to an audience of 50 influential individuals in business, finance, investments and philanthropy from around the world.  For more information on the work carried out by the The Buck Institute please click on the link.

 


13th October 2016

Centauri Therapeutics and the Horizon Discovery Group shortlisted for award  

Scrip awards

The 12th Annual Scrip Awards will take place at the Grosvenor House Hotel in London on 30th November 2016.  Centauri Therpeutics are delighted to announce that they have been shortlisted in the category of Best Partnership Alliance, along with the Horizon Discovery Group, for their immuno-oncology joint venture, Avvinity Therapeutics.  Please click here for more details of the event. 

 


28 September 2016

UK Bioscience Forum 2016

Representatives from Centauri Therapeutics will be attending the award winning UK Bioscience Forum 2016, which will take place on 20th October, at The Royal College of Surgeons in London.  The bioscience community will be gathering together for a day of partnering, networking and to enjoy presentations, discussions and debates.  For more details of the event, please click on the banner below 
  

Bio Science Forum 2016

 


23 September 2016

UN Pledges to fight the biggest threat to modern medicine - Antibiotic resistant bacteria

The 193 countries on the United Nations have agreed a landmark declaration to rid the world of drug-resistant infections.  Experts say that this international commitment could prevent upto 700,000 deaths a year.  Both BBC News and The Guardian have published articles on the declaration. Click on the links to read the items in full. 

 


12 September 2016

Centauri Therapeutics to attend OBN BioTuesday Antibiotic Resistance Event 

OPN Logo

Dr Mike Westby and Nick Higgins will be attending the meeting, to be held in Cambridge on 27th September. Antibiotic resistance is a threat that is becoming increasingly prevalent, leading to untreatable bacterial infections that may develop into a real and present danger to society. High quality presenters and panellists will help debate the challenge and opportunities in this field.  For more details of the event please click here

 


24 August 2016

Lord Heseltine visits the Discovery Park

Lord Heseltine was welcomed to The Discovery Park by representatives of companies based within the site, including the CEO of Centauri Therapeutics, Dr Mike Westby. 

Dr Mike Westby commented:

“Meeting Lord Heseltine and his team was a great opportunity to share my experience of running life science research at Sandwich.

“Discovery Park is a living example of how quickly a purpose-built Pharma R&D site can be evolved and repurposed to support tenants and encourage new investment.

“Only five years ago I was one of 2,400 Pfizer employees on a single occupancy site; today I lead one of over 150 different businesses in a thriving and diverse business park.”   

For more information on Lord Heseltine's visit, read the press release published on the Discovery Park website. 

 


22 August 2016

Centauri Therapeutics to attend Biotech and Money Assembly and Awards Gala Dinner 

Biotech logo

Centauri Therapeutics Limited will be among 275 people attending a gala dinner on 6th September, hosted by Biotech and Money, an influential community of senior life science decision makers.  The event will be celebrating the UK's funding, finance and investment successes in the sector over the last 12 months, with award winners and runners up in 7 categories being decided on the night, by live vote. 

Award catergories

award logos biotech

 

 


15 July 2016

Centauri Therapeutics welcomes industrial placement student 

This month Centauri welcomes industrial placement student Ben McNeilly, a chemistry undergraduate student from St. Andrews University. As an Enterprise Plus company with the RSC, Centauri was awarded a highly sought after one-year placement grant for an undergraduate student. Ben joins Centauri's industry experienced chemistry team to contribute to the novel linker and Alphamer platform. 


 8 July 2016

SE East Business interview Dr Mike Westby

South East Business, the magazine for leaders and business executives across Kent, Surrey and Sussex, has published an interview with Centauri CEO Mike Westby and co-director and investor, Jerry Biggs, CEO of NCL

http://www.southeastbusiness.com/section/features/race-against-time

 


 8 July 2016

Centauri Therapeutics extends research partnership with Peakdale Molecular

Peakdale Molecular Limited, a UK-based provider of drug discovery services to the pharmaceutical and biotech industries has signed an agreement to extend its research collaboration with Centauri Therapeutics, a UK based biotechnology company focussed on the discovery and development of novel molecules targeting life threatening diseases. Peakdale provides synthetic and analytical chemistry expertise for the continued development of Centauri’s Alphamer platform.

Alphamer technology is based on programmable immunity in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer, whereas the other end presents specific epitopes that attach to circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection.

Centauri acquired the Alphamer platform following the publication of a successful preclinical proof of principle study and continues to build the platform and drug discovery expertise necessary to exploit the exciting new approach. Centauri has been working closely with Peakdale’s experience team of chemists to synthesise and analyse the optimal linker for each bioconjugated Alphamer/aptamer.

Commenting on Centauri’s collaboration with Peakdale, Dr Mike Westby, CEO of Centauri said: “We have been delighted with the rapid progress made in the development of our Alphamer platform, with Peakdale chemists making a significant contribution to meeting our ambitious and demanding scientific objectives. We look forward to continuing to work with Peakdale in this new phase of the project.

Dr Paul Doyle, COO of Peakdale commented: “Centauri is operating in an exciting area in which expertise in complex synthetic and analytical chemistry is a key component. We are delighted that the decades of experience Peakdale has acquired combined with our partnership approach has demonstrated the value working with Peakdale can provide.”

http://www.manufacturingchemist.com/news/article_page/Centauri_Therapeutics_extends_research_partnership_with_Peakdale_Molecular/119562 

About Centauri Therapeutics Ltd

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.

Centauri Therapeutics has established a core R&D facility at Discovery Park in Sandwich, Kent, with an experienced team of industry scientists focused on discovery, optimisation and development of novel Alphamers targeting acute hospital acquired infections.

For more information about Centauri visit www.centauritherapeutics.com

About Peakdale Molecular Ltd

Peakdale Molecular (part of the Concept Life Sciences Group) is a leading UK-based provider of drug discovery services to the pharmaceutical, biotech, diagnostics and materials sciences.

Peakdale is renowned for skills in problem-solving and open communications, and our scientists pride themselves in seizing the initiative, providing energy, skill and creativity toward the project objectives. Peakdale Molecular operates on two sites, from our headquarters in the Peak District and at Discovery Park located at Sandwich, Kent.

For more information about Peakdale Molecular visit www.peakdale.co.uk

Notes to editors:

The Concept Life Sciences Group was created following the acquisition of Peakdale Molecular Limited, Scientific Analysis Laboratories Limited, Resource & Environmental Consultants Limited, CXR Biosciences and Agenda1 Analytical Services. The Group offers a comprehensive range of services to clients in the pharmaceutical, biotech, agrochemical, petrochemical, chemical, food, environmental and consumer industries.

For media information contact Sarah Roberts, Vane Percy & Roberts, +44 (0)1737 821890,  This email address is being protected from spambots. You need JavaScript enabled to view it.
For more information about Peakdale Molecular contact Gordon Woodrow, This email address is being protected from spambots. You need JavaScript enabled to view it.
For more information about Centauri Therapeutics contact Mel Glossop, This email address is being protected from spambots. You need JavaScript enabled to view it.

 


3 May 2016

Centauri Therapeutics have joined the BEAM Alliance, along with other companies developing anti-infectives: http://beam-alliance.eu/


2 March 2016

Centauri Therapeutics Limited Forms Joint Venture with Horizon Discovery Group plc

Creating Differentiated New Player in the Rapidly growing

Immuno-Oncology Market

  • Newly formed company Avvinity Therapeutics will be jointly managed by Centauri and Horizon, via its Research Biotech business
  • Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion
  • Avvinity will have exclusive rights in oncology to use Alphamer therapeutic platform,invented by a Nobel Laureate and developed by Centauri
  • Horizon to invest up to £5.3 million, with an initial outlay of £2.5 million, in a joint venture to identify novel immuno-oncology therapeutics
  • Horizon will contribute its gene editing technology platform and oncology expertise and will also benefit from service revenues from the joint venture
  • Formation of the joint venture represents a strategic move by Horizon to capture the upside potential of its IP, platform technologies and capabilities in immuno-oncology, synthetic lethality and cell therapy based therapeutics.

London and Kent, UK, 2 March 2016: Centauri Therapeutics Limited (“Centauri”), a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening infectious diseases has formed an immuno-oncology joint venture, Avvinity Therapeutics (“Avvinity”), with Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Company”), the leading international gene editing company.

Avvinity will combine Centauri’s Alphamer technology to provide a powerful and proprietary platform to discover and develop novel immuno-oncology therapeutics, for both solid tumours and leukaemias with Horizon’s gene editing, immunology, oncology and drug discovery capabilities. Avvinity will be targeting an immuno-oncology market currently worth £25 billion per year and expected to grow to approximately £50 billion per year by 2020.

Dr. Mike Westby, Chief Executive Officer of Centauri Therapeutics Limited, commented: Alphamers are an entirely novel way to target disease and represent an exciting new approach for recruitment of host immunity. At Centauri we have invested to build the Alphamer platform and assembled the drug discovery expertise necessary to exploit the platform in infectious diseases. Through this joint venture with Horizon, we look forward to applying our combined know-how and capabilities to develop Alphamers as important new immuno-oncology medicines, particularly for cancer indications that have proven intractable to date.”

For further information, please see the press release published 2nd March 2016 or visit the Avvinity website at www.avvinity.com.

 


18 January 2016                        

Centauri Therapeutics Ltd to Develop Novel Anti-Infective Therapeutics

 

  • Company has acquired Alphamer immuno-therapeutics platform technology
  • Initially focusing on anti-infective indications
  • Dr Clive Dix appointed as Chairman
  • Secured initial tranche of £3M financing, sufficient to develop first lead candidate

 

London and Kent, UK, 18 January 2016: Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases, announced today that it has acquired the Alphamer technology for drug discovery and development from Altermune Technologies LLC. Centauri Therapeutics acquired full rights to patents, proprietary compounds, know-how and collaboration/licence agreements from Altermune in exchange for an undisclosed fee.

The company has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate. The funding will be used to develop its first lead Alphamers against anti-microbial resistant (AMR) pathogens, which pose an increasing threat to human health. Investors include Animatrix Capital LLP, a regional investment fund, and private investors.

Centauri Therapeutics’ decision to acquire the Alphamer platform was made following the publication of a successful preclinical proof of principle study by Professor Victor Nizet, a professor at UCSD, California and a leading academic in the field of antimicrobial immunity.

Clive Dix has more than 25 years’ experience in the life sciences industry and is one of the UK’s leading pharma and biotech entrepreneurs. Clive was formerly co-founder and Chief Executive of Convergence Pharmaceuticals Ltd., acquired by Biogen Idec in 2015 in a deal worth up to $675 million. Previously, he was a founder and CEO of PowderMed Ltd, acquired by Pfizer in 2006; and Chairman of Auralis Ltd where he managed a successful US trade sale. Before that he was a main Board Director of PowderJect Pharmaceuticals plc until its acquisition by Chiron in 2003. 

Centauri Therapeutics has established a core R&D facility at Discovery Park in Sandwich, Kent, with an experienced team of industry scientists focused on discovery, optimisation and development of novel Alphamers targeting acute hospital acquired infections.

Mike Westby, CEO of Centauri Therapeutics, commented: “The emergence and rapid global spread of AMR pathogens means that there is a large potential market to treat life-threatening intractable diseases. Alphamers are chemically synthesised molecules designed to redirect the body’s own immune system to more effectively fight infection. As well as the new financing announced today we are also proud to announce the appointment of Clive Dix as our Chairman. Clive’s experience in successfully developing therapeutic platform technologies will be invaluable.”

Clive Dix, Chairman of Centauri Therapeutics, said: “The Alphamer platform technology is a unique opportunity to assemble well-characterised building blocks to produce novel and IP-protected medicines. Centauri Therapeutics has assembled a team of industry-experienced R&D scientists guided by a proven leadership.”

ENDS

 

For more information please contact:

Lorna Cuddon, Zyme Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

+44 (0)7811 996 942

About Centauri Therapeutics Ltd (www.centauritherapeutics.com)

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.

The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Centauri Therapeutics’ Executive team is led by Mike Westby, Chief Executive Officer (previously Pfizer, Roche) and Stuart Lawson, Chief Financial Officer (CEO of the private investment group Animatrix Capital LLP, and previously KPMG). Clive Dix is Non-Executive Director and Chairman of the Board (previously Convergence Pharmaceuticals, PowderMed, PowderJect, Glaxo Wellcome).

The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).

Centauri Therapeutics is based at Discovery Park, Kent. For more information about the company please visit www.centauritherapeutics.com


·         will be used to develop the Company’s Alphamer technology to target antibacterial resistance